HUP0203627A3 - N-guanidinoalkylamides, their preparation, their use, and pharmaceutical compositions comprising them - Google Patents

N-guanidinoalkylamides, their preparation, their use, and pharmaceutical compositions comprising them

Info

Publication number
HUP0203627A3
HUP0203627A3 HU0203627A HUP0203627A HUP0203627A3 HU P0203627 A3 HUP0203627 A3 HU P0203627A3 HU 0203627 A HU0203627 A HU 0203627A HU P0203627 A HUP0203627 A HU P0203627A HU P0203627 A3 HUP0203627 A3 HU P0203627A3
Authority
HU
Hungary
Prior art keywords
guanidinoalkylamides
preparation
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
HU0203627A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HUP0203627A2 publication Critical patent/HUP0203627A2/hu
Publication of HUP0203627A3 publication Critical patent/HUP0203627A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0203627A 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical compositions comprising them HUP0203627A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99121623A EP1095933A1 (en) 1999-10-30 1999-10-30 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
PCT/EP2000/010395 WO2001032611A1 (en) 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Publications (2)

Publication Number Publication Date
HUP0203627A2 HUP0203627A2 (hu) 2003-03-28
HUP0203627A3 true HUP0203627A3 (en) 2004-12-28

Family

ID=8239305

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203627A HUP0203627A3 (en) 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical compositions comprising them

Country Status (31)

Country Link
US (2) US6472562B1 (enExample)
EP (2) EP1095933A1 (enExample)
JP (1) JP4658430B2 (enExample)
KR (1) KR100981593B1 (enExample)
CN (1) CN1249026C (enExample)
AR (1) AR026257A1 (enExample)
AT (1) ATE264837T1 (enExample)
AU (1) AU776797B2 (enExample)
BR (1) BR0015186A (enExample)
CA (1) CA2389412C (enExample)
CZ (1) CZ301855B6 (enExample)
DE (1) DE60010113T2 (enExample)
DK (1) DK1228039T3 (enExample)
EE (1) EE05168B1 (enExample)
ES (1) ES2220553T3 (enExample)
HR (1) HRP20020372B1 (enExample)
HU (1) HUP0203627A3 (enExample)
IL (2) IL149209A0 (enExample)
ME (1) MEP54708A (enExample)
MX (1) MXPA02003805A (enExample)
NO (1) NO328016B1 (enExample)
NZ (1) NZ518607A (enExample)
PL (1) PL203859B1 (enExample)
PT (1) PT1228039E (enExample)
RS (1) RS50471B (enExample)
RU (1) RU2253651C2 (enExample)
SI (1) SI1228039T1 (enExample)
SK (1) SK286856B6 (enExample)
TR (1) TR200201181T2 (enExample)
WO (1) WO2001032611A1 (enExample)
ZA (1) ZA200203294B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644401B1 (en) * 2003-07-04 2011-03-09 Lonza AG Improved process for supported phase synthesis
PL3078743T3 (pl) 2007-09-28 2020-11-02 Portola Pharmaceuticals, Inc. Antidotum dla inhibitorów czynnika XA i sposoby ich stosowania
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
RU2377990C1 (ru) * 2008-07-23 2010-01-10 Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов
NZ592837A (en) 2008-11-14 2012-10-26 Portola Pharm Inc Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
ES2607935T3 (es) 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
DK2663309T3 (en) 2011-01-10 2017-06-19 Infinity Pharmaceuticals Inc METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
IL263680B2 (en) 2016-06-24 2025-10-01 Infinity Pharmaceuticals Inc PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer
CN110357800B (zh) * 2018-04-09 2022-07-26 青岛海生洋润生物科技有限公司 脯氨酸衍生物及其在制备治疗心脑血管疾病药物中的应用
CN115317474A (zh) * 2021-05-10 2022-11-11 中国海洋大学 一种苯酰胍衍生物在用于制备预防和治疗神经系统疾病或心血管系统疾病的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU206372B (en) * 1990-09-03 1992-10-28 Richter Gedeon Vegyeszet Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
CN1118209A (zh) 1993-01-20 1996-03-06 彼得·J·亚历山德罗维克斯 线监视系统
DE4326465A1 (de) 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
RU2152954C1 (ru) 1994-04-26 2000-07-20 Селектид Корпорейшн Ингибиторы фактора ха
PT798295E (pt) * 1994-12-02 2003-07-31 Yamanouchi Pharma Co Ltd Novo derivado de amidinonaftilo ou sal deste
US6342504B1 (en) * 1994-12-13 2002-01-29 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
WO1999010316A1 (en) * 1997-08-27 1999-03-04 Kissei Pharmaceutical Co., Ltd. 3-amidinoaniline derivatives, activated blood coagulation factor x inhibitors, and intermediates for producing both
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
HU227568B1 (en) 1997-12-24 2011-08-29 Sanofi Aventis Deutschland Indole derivatives, as inhibitors os factor xa
AU2074699A (en) * 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
US6348482B1 (en) * 1999-05-05 2002-02-19 Merck & Co., Inc. Catechols as antimicrobial agents

Also Published As

Publication number Publication date
JP2003513066A (ja) 2003-04-08
ATE264837T1 (de) 2004-05-15
CA2389412C (en) 2009-12-01
RU2002114041A (ru) 2004-01-20
NZ518607A (en) 2003-10-31
BR0015186A (pt) 2002-07-23
EP1228039B1 (en) 2004-04-21
EE200200199A (et) 2003-06-16
NO20022022L (no) 2002-04-29
AU1026501A (en) 2001-05-14
TR200201181T2 (tr) 2002-09-23
SK5782002A3 (en) 2002-10-08
HRP20020372A2 (en) 2004-08-31
CZ301855B6 (cs) 2010-07-14
CN1387508A (zh) 2002-12-25
IL149209A (en) 2007-06-03
AU776797B2 (en) 2004-09-23
KR100981593B1 (ko) 2010-09-13
US6472562B1 (en) 2002-10-29
SI1228039T1 (en) 2004-10-31
ES2220553T3 (es) 2004-12-16
CZ20021489A3 (cs) 2002-07-17
DE60010113D1 (de) 2004-05-27
EP1095933A1 (en) 2001-05-02
PL203859B1 (pl) 2009-11-30
EE05168B1 (et) 2009-06-15
MXPA02003805A (es) 2004-10-15
DK1228039T3 (da) 2004-08-16
HRP20020372B1 (hr) 2011-01-31
CA2389412A1 (en) 2001-05-10
US20030162967A1 (en) 2003-08-28
CN1249026C (zh) 2006-04-05
AR026257A1 (es) 2003-02-05
NO20022022D0 (no) 2002-04-29
PT1228039E (pt) 2004-09-30
JP4658430B2 (ja) 2011-03-23
YU29702A (sh) 2005-06-10
ZA200203294B (en) 2003-01-29
IL149209A0 (en) 2002-11-10
DE60010113T2 (de) 2005-05-04
WO2001032611A1 (en) 2001-05-10
RS50471B (sr) 2010-03-02
EP1228039A1 (en) 2002-08-07
RU2253651C2 (ru) 2005-06-10
PL354808A1 (en) 2004-02-23
US6664393B2 (en) 2003-12-16
SK286856B6 (sk) 2009-06-05
MEP54708A (en) 2011-05-10
NO328016B1 (no) 2009-11-09
KR20020047310A (ko) 2002-06-21
HK1050673A1 (en) 2003-07-04
HUP0203627A2 (hu) 2003-03-28

Similar Documents

Publication Publication Date Title
HUP0204081A3 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0204514A3 (en) Pyridinylimidazoles, pharmaceutical compositions containing them and their use
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
HUP0400837A3 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0204413A3 (en) Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them
HUP0204474A3 (en) 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
IL151209A0 (en) Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
HUP0301573A3 (en) Substituted arylpyrazines, pharmaceutical compositions containing them and their use
HUP0105003A3 (en) 2-oxy-4h-3,1-benzoxazin-4-one derivatives, their use and pharmaceutical compositions containing them
HUP0203194A3 (en) Phenylpiperazines, pharmaceutical compositions containing them and their use
HUP0102766A3 (en) Aminomethylcarboxylic acid derivatives, their pharmaceutical use and pharmaceutical compositions comprising them
IL148876A0 (en) Sulfonamide derivatives, their preparation and pharmaceutical compositions containing them
HUP0103884A3 (en) Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
HUP0203735A3 (en) 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0202781A3 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
HUP0400967A3 (en) Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them
SI1043307T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
HUP0203627A3 (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical compositions comprising them
HUP0201692A3 (en) Streptogramin derivatives, preparation and compositions containing them
HUP0104834A3 (en) Sulphonyloxazolamines, their use, pharmaceutical compositions containing them and their preparation
HUP0201910A3 (en) Novel aminobenzophenones, pharmaceutical compositions containing them and their use
HUP0401713A3 (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
HUP0202223A3 (en) Pseudomycin prodrugs, pharmaceutical compositions comprising thereof and their use
HUP0201810A3 (en) Sootepenseone and its derivatives, their preparation and use as medicament

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished